Lunbotinib vs Pralsetinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: RET · full Non-Small Cell Lung Cancer pipeline
Lunbotinib
Developed by Ellipses Pharma under a licence from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2027 · NCT05443126 (registry estimate)
No aligned efficacy figure on record for this race.
Pralsetinib
Marketed by Rigel Pharmaceuticals and partners
NCT04222972 · Phase 3 · terminated
This was a randomized, active-controlled trial in 223 patients that met its primary progression-free-survival endpoint with a clear statistical result, but it was conducted open-label (patients and investigators knew which treatment was given), which limits confidence in an investigator-assessed endpoint like progression.
Next expected readout: November 2026 · NCT04302025 (registry estimate)
Reported efficacy
Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5) (met)
Result source: NCT04222972
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Lunbotinib | Pralsetinib |
|---|---|---|
| PFS, median | —Not reported | 18.7 vs 9vs SOCNCT042229726 other results
|
| OS, median | —Not reported | 39.7bNCT030373854 other results
|
| ORR | —Not reported | 65.5% vs 41.6%vs SOCNCT0422297218 other results
|
| Duration of response, median | —Not reported | 20.6 vs 9.7vs SOCNCT042229727 other results
|
PFS, median
- Lunbotinib
- —Not reported
- Pralsetinib
- 18.7 vs 9vs SOCNCT04222972
6 other results
- 16.4 NCT03037385
- 12.1 NCT03037385
- 13 NCT03037385
- 24.9 NCT03037385
- 55.3 NCT03037385
- 7 NCT03037385
OS, median
- Lunbotinib
- —Not reported
- Pralsetinib
- 39.7bNCT03037385
4 other results
- 50.1 NCT03037385
- 46 NCT03037385
- 42.2 NCT03037385
- 10.3 NCT03037385
ORR
- Lunbotinib
- —Not reported
- Pralsetinib
- 65.5% vs 41.6%vs SOCNCT04222972
18 other results
- 63.1% NCT03037385
- 78.3% NCT03037385
- 73.9% NCT03037385
- 56.7% NCT03037385
- 77.8% NCT03037385
- 85.2% NCT03037385
- 46.4% NCT03037385
- 19% NCT03037385
- 7.7% NCT03037385
- 41.7% NCT03037385
- 45.5% NCT03037385
- 38.5% NCT03037385
- 25% NCT03037385
- 75% NCT03037385
- 40% NCT03037385
- 80% NCT03037385
- 50% NCT03037385
- 0% NCT03037385
Duration of response, median
- Lunbotinib
- —Not reported
- Pralsetinib
- 20.6 vs 9.7vs SOCNCT04222972
7 other results
- 31.8 NCT03037385
- 13.4 NCT03037385
- 22.6 NCT03037385
- 21.7 NCT03037385
- 51.8 NCT03037385
- 11.1 NCT03037385
- 5.5 NCT03037385
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Lunbotinib: no structured comparison results are available for Non-Small Cell Lung Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Lunbotinib: 0 of 4 rows · Pralsetinib: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Pralsetinib |
|---|---|
| Dropout rate | n/a: no completion milestonea NCT04222972 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 10 more resultsn/a: no completion milestone400 mg NCT03037385 · Phase 1/2 —400 mg QD NCT03037385 · Phase 1/2 n/a: no completion milestone600 mg NCT03037385 · Phase 1/2 n/a: no completion milestone300 mg NCT03037385 · Phase 1/2 n/a: no completion milestone200 mg NCT03037385 · Phase 1/2 n/a: no completion milestone200/100 mg NCT03037385 · Phase 1/2 n/a: no completion milestone100 mg NCT03037385 · Phase 1/2 n/a: no completion milestone100/100 mg NCT03037385 · Phase 1/2 n/a: no completion milestone60 mg NCT03037385 · Phase 1/2 n/a: no completion milestone30 mg NCT03037385 · Phase 1/2 |
| Discontinued due to AEs | 0.9%a NCT04222972 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 10 more results0%400 mg NCT03037385 · Phase 1/2 —400 mg QD NCT03037385 · Phase 1/2 0%600 mg NCT03037385 · Phase 1/2 0%300 mg NCT03037385 · Phase 1/2 0%200 mg NCT03037385 · Phase 1/2 0%200/100 mg NCT03037385 · Phase 1/2 20%100 mg NCT03037385 · Phase 1/2 0%100/100 mg NCT03037385 · Phase 1/2 0%60 mg NCT03037385 · Phase 1/2 0%30 mg NCT03037385 · Phase 1/2 |
| Serious AEs | 62%a NCT04222972 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 10 more results—400 mg NCT03037385 · Phase 1/2 70.6%400 mg QD NCT03037385 · Phase 1/2 —600 mg NCT03037385 · Phase 1/2 —300 mg NCT03037385 · Phase 1/2 —200 mg NCT03037385 · Phase 1/2 —200/100 mg NCT03037385 · Phase 1/2 —100 mg NCT03037385 · Phase 1/2 —100/100 mg NCT03037385 · Phase 1/2 —60 mg NCT03037385 · Phase 1/2 —30 mg NCT03037385 · Phase 1/2 |
| Most frequent reported AEs | a anaemia 48.1% constipation 43.5% aspartate aminotransferase increased 41.7% NCT04222972 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 1 more result400 mg QD anaemia 52.8% aspartate aminotransferase increased 50.6% constipation 44.1% NCT03037385 · Phase 1/2 |
Notes
- aPopulation comparability has not been reviewed for 10 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Pralsetinib
show 17 more results
show 8 more results
show 8 more results
show 8 more results
show 6 more results
show 6 more results
+ 4 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lunbotinib's landscape · Pralsetinib's landscape